Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hyperfine, Inc. stock logo
HYPR
Hyperfine
$1.28
+0.8%
$0.94
$0.53
$1.90
$99.63M1.061.43 million shs145,912 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$0.48
-7.6%
$0.43
$0.16
$2.31
$29.25M0.6719.61 million shs5.79 million shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$3.24
+1.3%
$4.61
$3.03
$9.33
$53.27M1.34190,393 shs64,624 shs
Zynex Inc. stock logo
ZYXI
Zynex
$1.54
-1.3%
$2.17
$1.23
$9.42
$46.66M0.91261,904 shs112,894 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hyperfine, Inc. stock logo
HYPR
Hyperfine
-1.55%+5.83%+38.03%+115.25%+18.14%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-2.42%-28.42%+40.81%+54.22%-67.31%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
-3.32%-2.14%-26.27%-32.06%-54.61%
Zynex Inc. stock logo
ZYXI
Zynex
+2.63%-1.27%-32.47%-31.28%-79.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hyperfine, Inc. stock logo
HYPR
Hyperfine
1.5218 of 5 stars
1.35.00.00.02.51.70.6
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.8 of 5 stars
3.35.00.00.02.80.00.6
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
1.7458 of 5 stars
3.51.00.00.02.11.70.0
Zynex Inc. stock logo
ZYXI
Zynex
2.4348 of 5 stars
3.21.00.00.01.81.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hyperfine, Inc. stock logo
HYPR
Hyperfine
2.67
Moderate Buy$1.280.26% Upside
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.60
Moderate Buy$8.881,735.19% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.00
Buy$8.00146.91% Upside
Zynex Inc. stock logo
ZYXI
Zynex
2.33
Hold$4.90218.18% Upside

Current Analyst Ratings Breakdown

Latest PSTV, HYPR, SRTS, and ZYXI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$4.00 ➝ $3.00
8/15/2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$0.68 ➝ $0.85
8/14/2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $2.00
8/12/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $8.00
8/8/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $6.00
8/1/2025
Zynex Inc. stock logo
ZYXI
Zynex
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$3.70
8/1/2025
Zynex Inc. stock logo
ZYXI
Zynex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
7/15/2025
Zynex Inc. stock logo
ZYXI
Zynex
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $3.00
6/30/2025
Zynex Inc. stock logo
ZYXI
Zynex
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/27/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.50 ➝ $3.00
6/25/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$9.00
(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hyperfine, Inc. stock logo
HYPR
Hyperfine
$10.80M9.23N/AN/A$0.45 per share2.84
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$5.82M5.03N/AN/A$0.05 per share9.67
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$41.81M1.27$0.42 per share7.66$3.17 per share1.02
Zynex Inc. stock logo
ZYXI
Zynex
$144.81M0.32$0.25 per share6.22$0.04 per share38.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hyperfine, Inc. stock logo
HYPR
Hyperfine
-$40.72M-$0.52N/AN/AN/A-364.54%-84.82%-69.39%N/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$12.98M-$2.24N/AN/AN/A-357.85%N/A-117.72%N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M-$0.06N/A14.09N/A-2.26%-1.58%-1.41%N/A
Zynex Inc. stock logo
ZYXI
Zynex
$2.99M-$0.94N/A3.28N/A-19.79%-78.54%-16.70%10/30/2025 (Estimated)

Latest PSTV, HYPR, SRTS, and ZYXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.09-$0.01+$0.08-$0.01$1.08 million$1.39 million
8/13/2025Q2 2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
-$0.12-$0.12N/A-$0.12$3.00 million$2.70 million
8/7/2025Q2 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.01-$0.06-$0.07-$0.06$9.30 million$7.32 million
5/30/2025Q1 2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hyperfine, Inc. stock logo
HYPR
Hyperfine
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
Zynex Inc. stock logo
ZYXI
Zynex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hyperfine, Inc. stock logo
HYPR
Hyperfine
N/A
5.02
4.41
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
1.26
1.03
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
8.14
5.79
Zynex Inc. stock logo
ZYXI
Zynex
0.56
0.62
0.45

Institutional Ownership

CompanyInstitutional Ownership
Hyperfine, Inc. stock logo
HYPR
Hyperfine
15.03%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%
Zynex Inc. stock logo
ZYXI
Zynex
29.68%

Insider Ownership

CompanyInsider Ownership
Hyperfine, Inc. stock logo
HYPR
Hyperfine
30.98%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.79%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
Zynex Inc. stock logo
ZYXI
Zynex
49.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hyperfine, Inc. stock logo
HYPR
Hyperfine
19077.83 million53.72 millionOptionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2060.49 million60.01 millionNot Optionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.44 million14.98 millionOptionable
Zynex Inc. stock logo
ZYXI
Zynex
77030.30 million15.37 millionOptionable

Recent News About These Companies

Contrasting Zynex (NASDAQ:ZYXI) & United Health Products (OTCMKTS:UEEC)
Zynex announces new executive team
Zynex welcomes Steve Dyson as CEO, adds to leadership team
Zynex Q2 Revenue Drops 55%
Zynex Inc. Faces Challenges Amid Strategic Shifts
Zynex, Inc. (ZYXI) Q2 2025 Earnings Call Transcript
Zynex Reports Second Quarter 2025 Financial Results
Zynex Sets Second Quarter 2025 Earnings Call
Zynex: New CEO Steven Dyson shares his vision – ICYMI
Zynex: New CEO Steven Dyson shares his vision – ICYMI

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hyperfine stock logo

Hyperfine NASDAQ:HYPR

$1.28 +0.01 (+0.79%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 -0.03 (-2.27%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

Plus Therapeutics stock logo

Plus Therapeutics NASDAQ:PSTV

$0.48 -0.04 (-7.55%)
Closing price 04:00 PM Eastern
Extended Trading
$0.48 +0.00 (+0.29%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$3.24 +0.04 (+1.25%)
Closing price 04:00 PM Eastern
Extended Trading
$3.24 -0.01 (-0.15%)
As of 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

Zynex stock logo

Zynex NASDAQ:ZYXI

$1.54 -0.02 (-1.28%)
Closing price 04:00 PM Eastern
Extended Trading
$1.55 +0.01 (+0.65%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.